Skip to main content
. 2023 Aug 17;23(2):262–271. doi: 10.17998/jlc.2023.07.17

Table 3.

Summary of efficacy of lenvatinib post immunotherapy in retrospective cohorts

Study Objective response rate Disease control rate Median PFS (months) Median OS (months)
Gile et al.31 Not provided Not provided 4 13
Yoo et al.30 3 (15.8) 12 (63.2) 6.1 11.2

Values are presented as number or number (%).

PFS, progression-free survival; OS, overall survival.